Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-288.28	-465.89	-373.63	-295.35	-241.85
Depreciation & Amortization	1.51	1.1	0.53	0.47	0.41
Stock-Based Compensation	98.13	79.88	49.74	31.63	26.87
Other Adjustments	7.59	2.09	2.41	0.8	-
Change in Receivables	-80.65	-53.82	-	-	-
Changes in Inventories	-36.98	-34.07	-	-	-
Changes in Accounts Payable	5.28	15.56	4.21	2.45	20.36
Changes in Accrued Expenses	131.9	34.72	-1.48	36.41	9.83
Changes in Other Operating Activities	-28.05	-34.73	-6.01	-1.26	0.46
Operating Cash Flow	-189.55	-455.57	-324.23	-224.86	-183.92
Capital Expenditures	-0.47	-1.46	-1.48	-0.22	-0.21
Purchases of Intangible Assets	-3	-5	-	-	-
Purchases of Investments	-1,048	-1,131	-834.44	-143.48	-394.12
Proceeds from Sale of Investments	1,083	863.28	333.4	350.38	389.27
Investing Cash Flow	32.32	-274.39	-502.52	206.69	-5.06
Long-Term Debt Issued	350	-	65	50	-
Long-Term Debt Repaid	-121.66	-	-	-	-
Net Long-Term Debt Issued (Repaid)	228.34	-	65	50	-
Issuance of Common Stock	38.06	735.06	530.48	264.34	171.24
Net Common Stock Issued (Repurchased)	38.06	735.06	530.48	264.34	171.24
Other Financing Activities	-10.41	-	-0.36	-0.89	-
Financing Cash Flow	255.98	735.06	595.12	313.45	171.24
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.01	-	-	-	-
Net Cash Flow	98.76	5.1	-231.63	295.28	-17.74
Free Cash Flow	-190.02	-457.03	-325.71	-225.07	-184.13
FCF Margin	-19.83%	-253.72%	-	-	-
Free Cash Flow Per Share	-8.47	-21.48	-17.43	-13.13	-11.14
Levered Free Cash Flow	13.25	-484.78	-312.86	-207.5	-211
Unlevered Free Cash Flow	-226.9	-516.76	-384.72	-255.72	-211.64

Updated Feb 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q